Evolving Paradigms in the Treatment of Newly Diagnosed Multiple Myeloma

View More View Less
  • 1 From the Myeloma Unit, Division of Hematology, University of Torino, AOU San Giovanni Battista, Torino, Italy.
Restricted access

The treatment of multiple myeloma has undergone significant changes in the past few years. The introduction of novel agents, such as the immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor bortezomib, has dramatically improved the outcome of this disease and considerably increased the treatment options available. Several trials have shown the advantages linked to the use of novel agents both in young patients, who are considered eligible for transplantation, and elderly patients, for whom a conventional therapy should be considered. These novel agents may increase the efficacy of autologous stem cell transplantation with deeper and long-lasting response. In the transplant setting, different novel agent combinations have proved to be superior to the traditional vincristine-doxorubicin-dexamethasone. Similarly, novel agents have also changed the treatment paradigm of patients not eligible for transplantation, thus replacing the traditional melphalan-prednisone approach. Preliminary data also support the role of consolidation and maintenance therapy to further improve outcomes. This article provides an overview of the latest strategies, including novel agents used to treat patients with multiple myeloma, both in the transplant and nontransplant settings.

Correspondence: Antonio Palumbo, MD, Myeloma Unit, Division of Hematology, University of Torino, AOU San Giovanni Battista, Via Genova 3, 10126 Torino, Italy. E-mail: appalumbo@yahoo.com
  • 1

    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277300.

  • 2

    Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:25212526.

    • Search Google Scholar
    • Export Citation
  • 3

    Kumar SK, Rajkumar SV, Dispenzieri A. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:25162520.

  • 4

    Durie BG, Kyle RA, Belch A. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003;4:379398.

    • Search Google Scholar
    • Export Citation
  • 5

    Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:39.

    • Search Google Scholar
    • Export Citation
  • 6

    Kyle RA, Remstein ED, Therneau TM. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356:25822590.

    • Search Google Scholar
    • Export Citation
  • 7

    Kyle RA, Durie BG, Rajkumar SV. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:11211127.

    • Search Google Scholar
    • Export Citation
  • 8

    Greipp PR, San Miguel J, Durie BG. International staging system for multiple myeloma. J Clin Oncol 2005;23:34123420.

  • 9

    Fonseca R, Barlogie B, Bataille R. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:15461558.

  • 10

    Dewald GW, Therneau T, Larson D. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005;106:35533558.

    • Search Google Scholar
    • Export Citation
  • 11

    Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. Lyon, France: IARC Press; 2004.

    • Search Google Scholar
    • Export Citation
  • 12

    Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:18601873.

  • 13

    Harousseau JL, Avet-Loiseau H, Attal M. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 2009;27:57205726.

    • Search Google Scholar
    • Export Citation
  • 14

    Gay F, Larocca A, Wijermans P. Complete response correlates with long-term progression-free and overall survivals in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 2011;117:30253031.

    • Search Google Scholar
    • Export Citation
  • 15

    Paiva B, Martinez-Lopez J, Vidriales MB. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011;29:16271633.

    • Search Google Scholar
    • Export Citation
  • 16

    San Miguel JF, Almeida J, Mateo G. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002;99:18531856.

    • Search Google Scholar
    • Export Citation
  • 17

    Koreth J, Cutler CS, Djulbegovic B. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007;13:183196.

    • Search Google Scholar
    • Export Citation
  • 18

    Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33:8689.

  • 19

    Rajkumar SV, Rosiñol L, Hussein M. A multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone versus dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:21712177.

    • Search Google Scholar
    • Export Citation
  • 20

    Zonder JA, Crowley J, Hussein MA. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010;116:58385841.

    • Search Google Scholar
    • Export Citation
  • 21

    Rajkumar SV, Jacobus S, Callander NS. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:2937.

    • Search Google Scholar
    • Export Citation
  • 22

    Palumbo A, Rajkumar SV, Dimopoulos MA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414423.

    • Search Google Scholar
    • Export Citation
  • 23

    Jagannath S, Durie BG, Wolf J. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776783.

    • Search Google Scholar
    • Export Citation
  • 24

    Harousseau JL, Attal M, Avet-Loiseau H. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:46214629.

    • Search Google Scholar
    • Export Citation
  • 25

    Lokhorst HM, Schmidt-Wolf I, Sonneveld P. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008;93:124127.

    • Search Google Scholar
    • Export Citation
  • 26

    Popat R, Oakervee HE, Hallam S. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008;141:512516.

    • Search Google Scholar
    • Export Citation
  • 27

    Jakubowiak AJ, Kendall T, Al-Zoubi A. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009;27:50155022.

    • Search Google Scholar
    • Export Citation
  • 28

    Cavo M, Tacchetti P, Patriarca F. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:20752085.

    • Search Google Scholar
    • Export Citation
  • 29

    Rosiñol L, Cibeira MA, Martinez J. Thalidomide/dexamethasone (TD) vs. bortezomib (velcade)/thalidomide/dexamethasone (VTD) vs. VBMCP/VBAD/velcade as induction regimens prior autologous stem cell transplantation (ASCT) in multiple myeloma (MM): results of a phase III PETHEMA/GEM trial [abstract]. Blood 2009;114:Abstract 130.

    • Search Google Scholar
    • Export Citation
  • 30

    Moreau P, Facon T, Attal M. Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): results of IFM2007-02 study [abstract]. J Clin Oncol 2010;28:Abstract 8014.

    • Search Google Scholar
    • Export Citation
  • 31

    Richardson PG, Weller E, Lonial S. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679686.

    • Search Google Scholar
    • Export Citation
  • 32

    Knop S, Liebisch P, Wandt H. Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction in newly diagnosed multiple myeloma: results of an interim analysis of the German DSMM Xia trial [abstract]. J Clin Oncol 2009;27:Abstract 8516.

    • Search Google Scholar
    • Export Citation
  • 33

    Morgan GJ, Davies FE, Gregory WM. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011;118:12311238.

    • Search Google Scholar
    • Export Citation
  • 34

    Kumar SK, Flinn I, Noga SJ. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia 2010;24:13501356.

    • Search Google Scholar
    • Export Citation
  • 35

    McCarthy PL, Owzar K, Anderson KC. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract]. Blood 2010;116:Abstract 37.

    • Search Google Scholar
    • Export Citation
  • 36

    Attal M, Lauwers VC, Marit G. Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02 [abstract]. Blood 2010;116:Abstract 310.

    • Search Google Scholar
    • Export Citation
  • 37

    Barlogie B, Anaissie E, van Rhee F. Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J Clin Oncol 2010;28:30233027.

    • Search Google Scholar
    • Export Citation
  • 38

    Attal M, Harousseau JL, Facon T. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:24952502.

    • Search Google Scholar
    • Export Citation
  • 39

    Cavo M, Tosi P, Zamagni E. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:24342441.

    • Search Google Scholar
    • Export Citation
  • 40

    Fermand JP, Katsahian S, Divine M. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:92279233.

    • Search Google Scholar
    • Export Citation
  • 41

    Palumbo A, Cavallo F, Hardan I. A phase III study to compare melphalan, prednisone, lenalidomide (MPR) versus melphalan 200 mg/m2 and autologous transplantation (MEL200) in newly diagnosed multiple myeloma patients [abstract]. Blood 2010;116:Abstract 3573.

    • Search Google Scholar
    • Export Citation
  • 42

    Bladé J, Rosiñol L, Cibeira MT. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010;115:36553663.

  • 43

    Myeloma trialists’ Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998;16:38323842.

    • Search Google Scholar
    • Export Citation
  • 44

    Ludwig H, Hajek R, Tóthová E. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009;113:34353442.

    • Search Google Scholar
    • Export Citation
  • 45

    Facon T, Mary JY, Hulin C. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:12091218.

    • Search Google Scholar
    • Export Citation
  • 46

    Hulin C, Facon T, Rodon P. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:36643670.

    • Search Google Scholar
    • Export Citation
  • 47

    Beksac M, Haznedar R, Firatli-Tuglular T. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol 2011;86:1622.

    • Search Google Scholar
    • Export Citation
  • 48

    Waage A, Gimsing P, Fayers P. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010;116:14051412.

    • Search Google Scholar
    • Export Citation
  • 49

    Wijermans P, Schaafsma M, Termorshuizen F. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 2010;28:31603166.

    • Search Google Scholar
    • Export Citation
  • 50

    Palumbo A, Bringhen S, Liberati AM. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112:31073114.

    • Search Google Scholar
    • Export Citation
  • 51

    Waage A, Palumbo A, Fayers P. MP versus MPT for previously untreated elderly patients with multiple myeloma: a meta-analysis of 1,682 individual patient data from six randomized clinical trials [abstract]. J Clin Oncol 2010;28:Abstract 8130.

    • Search Google Scholar
    • Export Citation
  • 52

    San Miguel JF, Schlag R, Khuageva NK. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906917.

    • Search Google Scholar
    • Export Citation
  • 53

    Mateos MV, Richardson PG, Schlag R. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28:22592266.

    • Search Google Scholar
    • Export Citation
  • 54

    Mateos MV, Oriol A, Martínez-López J. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010;11:934941.

    • Search Google Scholar
    • Export Citation
  • 55

    Palumbo A, Falco P, Corradini P. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network. J Clin Oncol 2007;25:44594465.

    • Search Google Scholar
    • Export Citation
  • 56

    Palumbo A, Delforge M, Catalano J. A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients ≥ 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens [abstract]. Blood 2010;116:Abstract 622.

    • Search Google Scholar
    • Export Citation
  • 57

    Palumbo A, Bringhen S, Rossi D. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010;28:51015109.

    • Search Google Scholar
    • Export Citation
  • 58

    Palumbo A, Bringhen S, Petrucci MT. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104:30523057.

    • Search Google Scholar
    • Export Citation
  • 59

    Palumbo A, Gay F, Falco P. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 2010;28:800807.

    • Search Google Scholar
    • Export Citation
  • 60

    Bringhen S, Larocca A, Rossi D. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010;116:47454753.

  • 61

    Barlogie B, Anaissie E, van Rhee F. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176185.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 124 102 5
PDF Downloads 7 6 0
EPUB Downloads 0 0 0